SARA
LÓPEZ TARRUELLA COBO
Profesora asociada de Ciencias de la Salud
Publicaciones (78) Publicaciones de SARA LÓPEZ TARRUELLA COBO
2024
-
Correlation between breast cancer subtypes determined by immunohistochemistry and n-COUNTER PAM50 assay: a real-world study
Breast Cancer Research and Treatment, Vol. 203, Núm. 1, pp. 163-172
-
First-line therapy with palbociclib in patients with advanced HR+/HER2− breast cancer: The real-life study PALBOSPAIN
Breast Cancer Research and Treatment
2023
-
Assessment of a Genomic Assay in Patients with ERBB2 -Positive Breast Cancer Following Neoadjuvant Trastuzumab-Based Chemotherapy with or Without Pertuzumab
JAMA Oncology, Vol. 9, Núm. 6, pp. 841-846
-
Association of HER2DX with pathological complete response and survival outcomes in HER2-positive breast cancer
Annals of Oncology, Vol. 34, Núm. 9, pp. 783-795
-
Impact of the COVID-19 Lockdown on Physical Activity Levels and Health Parameters in Young Adults with Cancer
Current Oncology, Vol. 30, Núm. 6, pp. 5395-5408
-
Laser transfer for circulating tumor cell isolation in liquid biopsy
International Journal of Bioprinting, Vol. 9, Núm. 4, pp. 1-14
-
Long-term outcomes of high-risk HR-positive and HER2-negative early breast cancer patients from GEICAM adjuvant studies and El Álamo IV registry
Breast Cancer Research and Treatment, Vol. 201, Núm. 2, pp. 151-159
2022
-
A Standardized Liquid Biopsy Preanalytical Protocol for Downstream Circulating-Free DNA Applications
Journal of Visualized Experiments, Vol. 2022, Núm. 187
-
A prospective observational study for a Federated Artificial Intelligence solution for moniToring mental Health status after cancer treatment (FAITH): study protocol
BMC Psychiatry, Vol. 22, Núm. 1
-
HER2+ Breast Cancer Escalation and De-Escalation Trial Design: Potential Role of Intrinsic Subtyping
Cancers, Vol. 14, Núm. 3
-
How we treat HR-positive, HER2-negative early breast cancer
Future oncology (London, England), Vol. 18, Núm. 8, pp. 1003-1022
-
Residual cancer burden after neoadjuvant chemotherapy and long-term survival outcomes in breast cancer: a multicentre pooled analysis of 5161 patients
The Lancet. Oncology, Vol. 23, Núm. 1, pp. 149-160
-
The importance of physical exercise in cardiovascular fitness in breast cancer survivors. A cross-sectional study: women in Motion 2.0
Supportive Care in Cancer, Vol. 30, Núm. 8, pp. 6745-6754
2021
-
Activity of docetaxel, carboplatin, and doxorubicin in patient-derived triple-negative breast cancer xenografts
Scientific Reports, Vol. 11, Núm. 1
-
Assessment of diarrhea as side effect of oral targeted antineoplastic agents in clinical practice
Supportive Care in Cancer, Vol. 29, Núm. 8, pp. 4673-4681
-
Dpyd exome, mrna expression and uracil levels in early severe toxicity to fluoropyrimidines: An extreme phenotype approach
Journal of Personalized Medicine, Vol. 11, Núm. 8
-
Technical challenges for CTC implementation in breast cancer
Cancers, Vol. 13, Núm. 18
2020
-
Intratumoral nanoplexed poly I:C BO-112 in combination with systemic anti-PD-1 for patients with anti-PD-1-refractory tumors
Science Translational Medicine, Vol. 12, Núm. 565
-
Poly (ADP-ribose) Polymerase Inhibition in Patients with Breast Cancer and BRCA 1 and 2 Mutations
Drugs, Vol. 80, Núm. 2, pp. 131-146
-
Prospective, multicenter study on the economic and clinical impact of gene-expression assays in early-stage breast cancer from a single region: the PREGECAM registry experience
Clinical and Translational Oncology, Vol. 22, Núm. 5, pp. 717-724